Sangamo Therapeutics, Inc. (SGMO) Rises A lot Today, Is Now One of The Best Performer

December 7, 2017 - By Adrian Erickson

Investors sentiment increased to 1.59 in 2017 Q2. Its up 0.79, from 0.8 in 2017Q1. It improved, as 13 investors sold Sangamo Therapeutics, Inc. shares while 31 reduced holdings. 33 funds opened positions while 37 raised stakes. 50.83 million shares or 24.82% more from 40.72 million shares in 2017Q1 were reported.
Credit Suisse Ag reported 376,688 shares. Janney Montgomery Scott Ltd Limited Liability Company has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Tudor Invest Et Al holds 26,507 shares. Highlander Management Limited Liability Corporation stated it has 0.1% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Hightower Advisors Limited Liability Corporation has 29,405 shares for 0% of their portfolio. State Street reported 0% stake. Balyasny Asset Mngmt Limited Liability Company has 351,700 shares. Swiss Fincl Bank invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Fic Capital Inc has invested 3.48% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). D E Shaw And reported 0.02% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Susquehanna Intll Llp owns 203,734 shares. Massachusetts-based Ra Cap Management Limited Liability Corporation has invested 1.26% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Nelson Roberts Invest Advsrs Limited Com reported 3,000 shares or 0.01% of all its holdings. 43,231 are owned by Proshare Advsr Ltd Liability. Advisory Svcs Network invested 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO).

The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a huge mover today! The stock increased 5.20% or $0.85 during the last trading session, reaching $17.2. About 1.37 million shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since December 7, 2016 and is uptrending. It has outperformed by 13.08% the S&P500.
The move comes after 8 months positive chart setup for the $1.45B company. It was reported on Dec, 7 by We have $18.06 PT which if reached, will make NASDAQ:SGMO worth $72.70M more.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.23 EPS, down 64.29 % or $0.09 from last year’s $-0.14 per share. After $-0.15 actual EPS reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 53.33 % negative EPS growth.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Ratings Coverage

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 6 have Buy rating, 1 Sell and 3 Hold. Therefore 60% are positive. Sangamo Biosciences had 21 analyst reports since August 8, 2015 according to SRatingsIntel. Jefferies maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) rating on Wednesday, September 2. Jefferies has “Buy” rating and $12 target. Jefferies maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) rating on Tuesday, September 12. Jefferies has “Buy” rating and $18.0 target. The stock has “Buy” rating by JP Morgan on Thursday, September 3. PiperJaffray downgraded Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Wednesday, October 19 to “Neutral” rating. As per Friday, October 23, the company rating was reinitiated by Jefferies. On Wednesday, November 15 the stock rating was maintained by Wedbush with “Hold”. Jefferies maintained it with “Buy” rating and $18.0 target in Friday, October 13 report. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has “Buy” rating given on Thursday, June 22 by Jefferies. The firm earned “Overweight” rating on Wednesday, November 15 by PiperJaffray. The company was downgraded on Tuesday, November 1 by Wedbush.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: which released: “Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher” on November 16, 2017, also with their article: “Commit To Buy Sangamo Therapeutics At $8, Earn 21.9% Using Options” published on November 08, 2017, published: “Here’s Why Sangamo Therapeutics Rose as Much as 14.9% Thursday” on November 30, 2017. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: and their article: “Sangamo Announces Strategic Investment In Manufacturing And Appointment Of …” published on November 09, 2017 as well as‘s news article titled: “Sangamo Therapeutics: Engineering Genomic Solutions For Rare Diseases” with publication date: December 07, 2017.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.45 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: